3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

NCT04144413 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease With Severe Keratitis

Interventions

DRUG: Open-label Ikervis
DRUG: Masked Ikervis
OTHER: Vehicle Comparator: Masked Vehicle

Sponsor

Santen SAS